Ensysce BiosciencesENSCW 23 EBIT per Share is $0.00 as of Mar. 2026. GuruFocus rates ENSCW with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,181 Biotechnology companies, Ensysce Biosciences ranks better than 98.31% on this metric.
Ensysce Biosciences's EBIT per Share for the
three
months ended in Mar. 2026 was $0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.
During the past 3 years, the average EBIT per Share Growth Rate was 87.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 69.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Ensysce Biosciences's EBIT per Share or its related term are showing as below:
ENSCW'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 32.5 Med: 85.7 Max: 87.4
Current: 87.4
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Ensysce Biosciences was 87.40% per year. The lowest was 32.50% per year. And the median was 85.70% per year.
ENSCW's 3-Year EBIT Growth Rate is ranked better than 98.31% of 1181
companies
in the Biotechnology industry
Industry Median: 15.5
vs ENSCW: 87.40
Ensysce Biosciences (OTCPK:ENSCW) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Ensysce Biosciences EBIT per Share Related Terms
Ensysce Biosciences EBIT per Share Historical Data
* Premium members only.
The historical data trend for Ensysce Biosciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ensysce Biosciences (ENSCW) has a EBIT per Share of $0.00 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Ensysce Biosciences and its competitors. According to the industry distribution chart, Ensysce Biosciences ranks #20 out of 1181 companies in the Biotechnology industry, placing it in the top 1.7%.
Is Ensysce Biosciences' EBIT per Share too high?
Ensysce Biosciences' current EBIT per Share is $0.00. Based on the distribution chart, Ensysce Biosciences ranks #20 out of 1181 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ensysce Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Ensysce Biosciences' EBIT per Share compare to RNAZ and ALZN?
According to the Biotechnology industry distribution chart, Ensysce Biosciences ranks #20 out of 1181 companies for EBIT per Share. This places Ensysce Biosciences in the top 2% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Ensysce Biosciences and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ensysce Biosciences's current EBIT per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ensysce Biosciences stock overvalued right now?
Ensysce Biosciences (ENSCW) has a current EBIT per Share of $0.00. The current EBIT per Share is $0.00. Ensysce Biosciences' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Ensysce Biosciences (ENSCW), the current EBIT per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
23GF Score
Get the complete analysis for ENSCW
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENSCW has been successfully added to your 
